Acute Porphyria Drugs

Monograph

A10AE06 - Insulin Degludec
Not porphyrinogenic
NP

Rationale
Insulin degludec has no porphyrinogenic effects.
Chemical description
Antidiabetic pancreatic hormone consisting of polypeptide chains, connected by disulfide bridges.
Metabolism and pharmacokinetics
Insulin degludec is a basal insulin that forms soluble multi-hexamers upon subcutaneous injection, which are slowly and continuously absorbed into the bloodstream leading to a flat and stable glucose-lowering-effect. Degradation of insulin degludec is similar to that of human insulin; all metabolites formed are inactive.
Similar drugs
Explore alternative drugs in similar therapeutic classes A10A / A10AE or go back.
References
# Citation details PMID
*Scientific articles
1. Degludec, a new ultra-long-acting basal insulin for the treatment of diabetes mellitus type 1 and 2: advances in clinical research.
Muñoz Torres M. Endocrinol Nutr. 2014 Mar;61(3):153-9.
23890782
*Summary of Product Characteristics
2. The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Tresiba.

Tradenames

Tresiba Tresiba Tresiba Tresiba Tresiba Tresiba Tresiba Tresiba FlexTouch ยท Tresiba Penfill Tresiba Tresiba Tresiba Tresiba Tresiba Tresiba Tresiba Tresiba Tresiba Tresiba Tresiba
In cooperation with IpNet
© NAPOS 2025
An unhandled error has occurred. Reload ๐Ÿ—™